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Zusammenfassung 
 
Mit der Adipositas geht eine chronische Entzündung des Fettgewebes einher, welche 
durch Infiltration mit Makrophagen und Sekretion inflammatorischer Zytokine 
entscheidend an der Entstehung der Insulinresistenz und damit des Typ 2 Diabetes 
mellitus beteiligt ist. Osteopontin (OPN) ist ein inflammatorisches Zytokin, welches 
hauptsächlich von Makrophagen produziert und im humanen sowie murinen Fettgewebe 
bei Adipositas besonders stark exprimiert wird. Experimente in Mäusen deuteten auf 
eine wichtige Rolle von OPN bei der Entstehung der Fettgewebsentzündung und der 
Insulinresistenz hin, die zugrunde liegenden Mechanismen sind jedoch noch nicht näher 
bekannt. Dementsprechend war das Ziel dieser Arbeit, die Zielzellen der OPN-Wirkung 
im Fettgewebe zu identifizieren und die damit verbundenen molekularen Vorgänge 
näher zu untersuchen, um dadurch Rückschlüsse über die Entstehung der 
Fettgewebsentzündung  und Insulinresistenz zu erhalten. Zu diesem Zweck 
untersuchten wir die Wirkung von OPN auf humane Modellmakrophagen sowie 
isolierte humane Fettgewebsmakrophagen (ATMs), und humane und murine 
Zellkulturmodelle von Adipocyten.  
Stimulation mit OPN führte in humanen Makrophagen zu gesteigerter Produktion von 
pro- und anti-inflammatorischen Zytokinen (TNFα, Mcp-1 bzw. IL-10). Diese Zytokine 
wurden auch von humanen ATMs produziert, wobei die Stimulierbarkeit durch OPN in 
Abhängigkeit von der entsprechenden Aufreinigungsmethode schwankte. Behandlung 
mit OPN aktivierte außerdem die MAP Kinasen ERK und p38 und die Serin/Threonin 
Proteinkinase PKB/Akt, welche die Expression inflammatorischer Gene steuern. 
Außerdem aktivierte OPN in geringerem Ausmaß den NFκB Signalweg und zwar 
unabhängig vom LPS/TLR-4/IRAK Signalweg. Im Gegensatz dazu hatte OPN praktisch 
keine Wirkung auf die Insulinsensitivität und Differenzierungskapazität der Adipocyten.  
Unsere Daten weisen darauf hin, dass die Wirkung von OPN bei der Adipositas-
assoziierten Insulinresistenz primär über Anlockung und Aktivierung von Makrophagen 
und der damit verbundenen Fettgewebsentzündung, und nicht über direkte Interaktion 
mit Adipocyten erfolgt. 
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Abstract 
 
Obesity gives rise to a state of chronic low-grade inflammation that contributes to 
insulin resistance and type 2 diabetes and is characterized by the infiltration of adipose 
tissue macrophages (ATMs) into adipose tissue (AT) along with production of 
inflammatory cytokines. Osteopontin (OPN) is an inflammatory cytokine that is mainly 
produced by activated macrophages and whose expression in human and murine AT is 
markedly upregulated upon obesity. Previous animal experiments strongly suggested a 
critical role of OPN in the development of insulin resistance and AT inflammation but 
the underlying molecular processes are unknown so far. In this thesis, we sought to 
identify the target cells of OPN action in the inflamed AT and, as a consequence, 
alterations induced in the target cells that may lead to insulin resistance. We 
investigated the effect of OPN on adipose tissue macrophages and adipocytes by using 
human model macrophages as well as isolated ATMs, and human and murine adipocyte 
model systems.  
In both models of human macrophages, OPN induced secretion of inflammatory 
cytokines (TNFα, Mcp-1, IL-10), whereas human ATMs were also found to produce 
these cytokines, but responsiveness to OPN varied according to the isolation method 
used. In model macrophages, OPN treatment clearly induced activation of the MAP 
Kinase ERK, p38, and the serine/threonine kinase PKB/Akt, that are all associated with 
expression of inflammatory genes. The NFκB pathway was activated to a minor extent, 
notably independent from the LPS/TLR4/IRAK pathway. By contrast, OPN had no 
profound effect on insulin sensitivity or differentiation capacity of adipocytes.  
Taken together, these findings suggest that the primary role of OPN in obesity-
associated insulin resistance is the attraction and activation of macrophages with 
resulting AT inflammation, rather than direct interference with adipocyte function.  
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1 Introduction 
 
1.1 Obesity 
 
1.1.1 Physiological regulation of energy balance 
 
The mechanisms involved in body weight regulation are versatile and include genetic, 
physiological and behavioural factors. The maintenance of an adequate body weight is a 
major determinant of the survival of higher organisms and has been particularly 
important during evolution in periods of starvation. To ensure stability of body weight 
over long periods of time, a complex regulatory system is necessary that adjusts energy 
intake with energy expenditure (1).   
In healthy individuals, stable body weight is maintained by regulation of food intake 
and metabolic rate. Ingestion of food leads to a suppression of hunger and termination 
of food intake. This process is called satiation and is followed by a period that is 
characterized by the absence of hunger until the resurgence of the sensation of hunger 
(1, 2). Body size and composition also play a role in the control of energy balance: With 
undernutrition/weight loss, appetite increases and energy expenditure falls; with 
overfeeding/weight gain, appetite falls and energy expenditure increases (1, 3).  
Such adaptive feeding and metabolic responses involve brain pathways that sense 
changes in body fuel stores and exert powerful effects on energy balance1 (1, 4). The 
hypothalamus is the main regulatory organ for hunger and satiety in humans, integrating 
signals from the brain, the peripheral circulation and the gastrointestinal tract (5). 
The ease with which many individuals gain weight seems inconsistent with the concept 
of a robust regulatory system that controls body weight (4). High prevalence rates of 
obesity worldwide suggest that our regulatory systems defend against weight loss more 
effectively than against weight gain (4, 6, 7): the need to survive in environments with 
limited access to food is a much higher concern than to handle an overabundant food 
supply, which was unfrequent in the past and an uncommon threat to survival (4, 6, 8, 
9). Furthermore, it is evident that, in our modern civilizations, food intake is not 
necessarily the result of hunger. Numerous situations may lead to food or fluid 
                                                 
1 energy balance = the net difference between energy intake and expenditure 
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consumption as a result of social activities. Due to this massive overfeeding in the 
absence of hunger, many people override their physiological mechanisms of weight 
regulation and become obese (1). 
 
1.1.2 Epidemiology 
 
The worldwide prevalence of overweight and obesity has increased drastically during 
the last decades, and is now representing a major public health issue: Excessive weight 
is associated with an array of serious medical conditions, including insulin resistance, 
type 2 diabetes, fatty liver disease, atherosclerosis, cardiovascular disease, and some 
cancers, to name just a few examples (10). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Clustering of metabolic diseases (10) 
 
This cluster of pathologies has also started to emerge in children, which can be related 
to the similarly marked increase in obesity at young ages (10, 11).  
Today, the World Health Organisation estimates that more than 1 billion adults 
worldwide are overweight, defined as having a BMI2 of 25 to 29.9, or obese, defined by 
a BMI ≥ 30 (10, 12, 13). The rationale behind these definitions is based on 
epidemiological data that show increased mortality in subjects with BMIs ≥ 25 kg/m2. 
This increase in mortality, however, tends to be modest until a BMI of 30 kg/m2 is 
reached. Beyond this, mortality rates from all causes, and especially those from 
cardiovascular disease are increased by 50-100 % above that of lean subjects (12). If 
                                                 
2 The BMI is calculated as follows: BMI = weight (kg)/ height squared (m2) 
 
 8 
prevalence rates continue to rise, obesity is predicted to surpass smoking as the leading 
risk-factor for mortality3 within the next few years (14, 15). In some western countries 
as the United States, already more than 20% of the population can be classified as obese 
(16), demonstrating the enormous impact of obesity on public health issues.  
These data are not surprising, though, considering the lifestyle of the modern western 
civilization: Industrialization and its economic consequences have led to an increasingly 
urbanized and sedentary workforce, coupled with excessive caloric consumption due to 
easy access to food (14). Today, obesity along with its consequences is considered to be 
the epidemic of the 21st century.  
 
1.2 White adipose tissue 
 
1.2.1 Anatomical features 
 
Virtually all animal species have found a way to store excess energy in the form of fat 
for future needs. In most species, including humans, fat storage occurs predominantly in 
a mesodermal tissue, namely white adipose tissue (WAT), one of the two types of AT4 
(17).  
AT is a complex, essential, and highly active metabolic and endocrine organ. In addition 
to adipocytes, it contains connective tissue matrix, nerve tissue, stromavascular cells, 
and immune cells (18, 19). White fat cells/adipocytes contain one large fat vacuole and 
are therefore also referred to as unilocular fat cells.  
When an overabundance of energy is taken up, overweight or obesity develops, 
characterized by an expansion of AT. This enlargement of adipose mass is 
accomplished by an increase in adipocyte size (hypertrophy), and increase in fat cell 
number (hyperplasia) (19). 
 
 
 
 
                                                 
3 in the United States 
4 The other one is brown adipose tissue (BAT) whose primary purpose is to generate body heat. 
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1.2.2 Adipogenesis 
 
Adipocytes originate from mesenchymal/mesodermal stem cells by a sequential 
pathway of differentiation, i.e. adipogenesis. When subjected to appropriate 
developmental triggers, mesenchymal stem cells become committed to the adipocyte 
lineage. This differentiation presumably involves a common preadipocyte or adipoblast, 
which has the capacity to differentiate into white or brown preadipocytes (17).  
The process of terminal adipocyte differentiation during which preadipocytes mature 
into adipocytes has been extensively studied in murine 3T3-L1 and 3T3-F442A cell 
lines (17, 20). The signal for differentiation of new adipocytes is related to nutritional 
state. Important stimuli for differentiation include insulin and fatty acids. Fatty acids 
promote adipogenesis through members of the peroxisome proliferator-activated 
receptors (PPAR, particularly PPARγ), a family of nuclear receptors, i.e. ligand-
activated transcription factors. Natural ligands for PPAR are probably fatty acid 
derivatives (21, 22). In addition, differentiation is regulated by a pathway involving the 
sterol regulatory element binding protein-1c (SREBP-1c, also known as adipocyte 
determination and differentiation factor-1, ADD-1), a pathway that in adipocytes is 
regulated by insulin (21, 23, 24). 
 
1.2.3 Fat distribution 
 
In  humans, WAT is dispersed throughout the body in discrete depots. A major 
distinction can be drawn between visceral fat, which surrounds internal organs 
(intestines and other intra-abdominal organs as well as perirenal areas), and 
subcutaneous fat which is found underneath the skin mainly in the buttocks, thighs and 
abdomen. Other fat depots that are of metabolic or cardiovascular relevance are 
intramuscular and epicardial fat (17). 
Among these various AT depots, there is considerable heterogeneity, particularly with 
respects to metabolic risk (17, 18).  Increased subcutaneous fat in the thighs and hips 
(peripheral or pear-shaped obesity) exerts little or no risk of metabolic disease, whereas 
increased intra-abdominal/visceral fat (central or apple-shaped obesity) promotes a high 
risk (17, 25). This observed discrepancy in disease risk may be due to several reasons: 
First, the anatomic location of the AT depot is affecting endocrine function and disease 
risk. Endocrine hormones derived from subcutaneous AT are secreted into the systemic 
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circulation, whereas those derived from visceral AT are secreted into the portal system 
and have direct access to the liver thereby affecting hepatic metabolism (18).  In 
addition, metabolic activity is considered to vary between different AT depots: intra-
abdominal adipocytes have the highest metabolic activity5 followed by upper-body 
subcutaneous adipocytes, and lowest response in lower-body adipocytes (21, 26). Intra-
abdominal adipocytes have the highest rates of lipolysis and lipolysis is least susceptible 
to suppression by insulin here. In contrast, lower-body fat depots are more efficient at 
removing fat from the circulation and due to a lower rate of lipolysis they are relatively 
resistant to weight loss (21). 
Furthermore, adipokine expression and receptor expression patterns vary among 
different AT depots: For instance, expression and secretion of interleukin (IL)-6 and  
plasminogen activator inhibitor (PAI)-1 are relatively greater in visceral AT, whereas 
those of leptin and adiponectin is lower than in subcutaneous AT. Up to now, the 
precise mechanisms accounting for these differences are not fully elucidated, but this 
functional heterogeneity suggests that AT is probably rather a group of similar 
endocrine  organs than one single endocrine organ (18).   
 
1.2.4 Physiology 
 
Until the late 1980s, AT was considered as a passive organ with the only function to be 
the storage of excess energy as triglycerides, and its degradation and release of these 
lipids in the form of fatty acids according to need (27).  
Today, AT is known to exert, besides its role as energy store, important endocrine and 
paracrine function: AT is a major site for metabolism of steroid hormones and is 
secreting a variety of proteins that may either act locally or systemically to influence 
metabolism, endocrine, or immune function. In addition, AT expresses numerous 
receptors enabling it to respond to incoming signals, including those from the central 
nervous system (CNS). Hence, AT is involved in coordinating a variety of biological 
processes including energy metabolism, neuroendocrine function and immune function 
(18).  
 
                                                 
5 i.e. here: lipolysis 
 11 
1.2.5 Adipokines  
 
AT is by now well recognized as an endocrine organ which secretes a number of 
signaling peptides with diverse biological functions, collectively called adipokines (28-
31). They have important autocrine/paracrine roles in regulating adipocyte 
differentiation, metabolism, and local inflammatory responses (28, 30, 32-35). 
Adipokines also have important roles in the regulation of systemic lipid and glucose 
metabolism (28, 36-38) and the secretion of many adipokines is related to the degree of 
adiposity (28, 39-43).  
 
1.2.5.1 Classical adipokines – Leptin and adiponectin 
Leptin, a polypeptide with structural homology to cytokines, is the prototype for all 
adipose tissue-derived endocrine hormones (18).  
Adipocytes secrete leptin in direct proportion to adipose tissue mass and nutritional 
status (18). Accordingly, its primary role – besides other endocrine functions -  is to 
serve as a metabolic signal of energy sufficiency, primarily via hypothalamic pathways 
(18, 44). With caloric restriction and weight loss, leptin levels rapidly decline, leading 
to increased appetite and decreased energy expenditure, whereas massive obesity is 
often associated with elevated circulating leptin and an inability to respond to leptin 
(leptin resistance) (18, 45).  
Adiponectin (AdipoQ) is specifically produced by adipocytes and circulates at high  
levels in the bloodstream (18, 46-50).  In contrast to leptin, plasma adiponectin levels 
have been found to be decreased in states of obesity and insulin resistance and several 
studies have suggested an antidiabetic, antiinflammatory and antiatherogenic effect (18, 
50, 51). 
 
1.2.5.2 Inflammatory adipokines 
1.2.5.2.1 Tumor necrosis factor (TNF)α 
TNFα is an inflammatory cytokine that is secreted by the AT, mainly macrophages, but 
also adipocytes and other stromavascular cells (52). Its expression is increased in obese 
individuals and has been implicated in the pathogenesis of obesity and insulin resistance 
(53-56). 
1.2.5.2.2 IL-6 
IL-6 is another inflammatory cytokine that is expressed by the AT (57). In contrast to 
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TNFα, IL-6 circulates at high levels in the bloodstream, and both expression and 
circulating levels are positively correlated with obesity and insulin resistance (18, 56).   
 
1.2.5.2.3 Monocyte chemoattractant protein (Mcp)–1 
Mcp-1, a chemokine that recruits monocytes to sites of inflammation, is expressed and 
secreted by the AT. AT expression of Mcp-1 and circulating Mcp-1 levels are increased 
in rodent obesity, suggesting that Mcp-1-mediated macrophage infiltration of AT (see 
1.4.2.3) may contribute to insulin resistance (18, 34, 58-61). 
 
1.2.5.2.4 IL-10 
IL-10 is an anti-inflammatory cytokine produced by various cell types, such as activated 
monocytes, macrophages, lymphocytes, and keratinocytes. Obesity is associated with 
elevated circulating levels of IL-10 and the expression of IL-10 is increased in obese 
human and rodent AT (62, 63). As an anti-inflammatory cytokine, IL-10 has been 
shown to have a protective role on the formation and stability of atherosclerotic lesions 
in rodents (62, 64), while human subjects with low IL-10 serum levels have an 
increased risk of developing type 2 diabetes mellitus (62, 65).  
 
1.3 Insulin and insulin resistance 
 
1.3.1 Functions of insulin 
 
Insulin is the most potent anabolic hormone known and is essential for tissue 
development, growth, and maintenance of whole-body glucose homeostasis. It is 
secreted by the pancreatic β cells in response to increased circulating levels of glucose 
and amino acids after a meal (66). Insulin increases glucose uptake in muscle and fat 
and inhibits hepatic glucose production, thereby serving as the primary regulator of 
blood glucose, which is maintained at a concentration of 4 – 7 mM in healthy 
individuals. Insulin also promotes the storage of substrates in fat, liver and muscle by 
stimulating lipogenesis, glycogen and protein synthesis, and inhibiting lipolysis, 
glycogenolysis and protein breakdown (67).   
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1.3.2 Insulin signaling  
 
1.3.2.1 Insulin action 
Insulin increases glucose uptake in cells by stimulating the translocation of the glucose 
transporter GLUT4 from intracellular sites to the plasma membrane (67). Insulin action 
is initiated through the binding to and activation of its cell-surface receptor (Figure 2). 
The insulin receptor is a tyrosine kinase that undergoes tyrosine autophosphorylation 
upon activation and thereafter phosphorylates a number of cellular proteins on tyrosine  
(66-68), including members of the insulin-receptor substrate (IRS) family (66, 69). The 
phosphorylated tyrosines in these substrates act as docking sites for proteins that contain 
Src-homology-2 (SH2) domains, such as the regulatory subunit of the type 1A 
phosphatidylinositol 3-kinase (PI(3)K) (67), the activation of which may transmit 
multiple signals. PI(3)K catalyzes for instance the phosphorylation of phosphoinositides 
to phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P3 which bind to the 
pleckstrin homology (PH) domains of a variety of signaling molecules (67, 70). 
Phosphatidylinositol-3-phosphates induce, among others, the activation of the 
serine/threonine kinase Akt, which plays an important role in the transmission of the 
insulin signal (67, 71-73). This and other pathways (74-77)  act in a concerted fashion to 
coordinate the regulation of GLUT4 vesicle trafficking, protein synthesis, enzyme 
activation/inactivation, and gene expression, which results in the regulation of glucose, 
lipid and protein metabolism (67).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Signal transduction in insulin action (67) 
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1.3.2.2 Attenuation of insulin-receptor signaling 
In addition to tyrosine autophosphorylation, both the insulin receptor  and IRS proteins 
undergo serine phosphorylation, which impair insulin signaling (67, 78). Moreover, 
several protein tyrosine phosphatases (PTPases) catalyze dephosphorylation of the 
receptor and its substrates, thereby attenuating insulin action (66, 67). 
 
 
1.3.3 Insulin resistance 
 
1.3.3.1 Definition 
Insulin sensitivity is defined as the ability of insulin to reduce circulating glucose 
concentrations. Accordingly, insulin resistance is a condition in which greater 
concentrations of insulin are necessary to produce an adequate reduction of plasma 
glucose concentrations and in severe insulin resistance, even very high insulin 
concentrations cannot evoke a maximal response of glycemia that is achieved under 
physiological concentrations. 
 
1.3.3.2 Role of AT in insulin resistance 
Obesity is an important factor for  the development of insulin resistance.  Adipose tissue 
controls insulin sensitivity by releasing nonesterified fatty acids (NEFAs), hormones – 
including adiponectin, leptin, and resistin – and proinflammatory cytokines (79-82). In 
obesity, the production of many of these substances is disregulated. Fatty acids are 
supposed to cause insulin resistance by inhibiting glycolysis, leading to increased 
intracellular glucose-6-posphate concentrations that result in decreased glucose uptake 
(79, 83). An alternative mechanism has been proposed in which intracellular fatty acid 
metabolites lead to phosphorylation of serine/threonine sites on IRS-1 and IRS-2 
thereby reducing their ability to activate PI(3)K. As a consequence, glucose transport 
activity and other events downstream of insulin receptor signaling are diminished (79, 
84). 
In addition to fatty acids, increased release of TNFα, IL-6, Mcp-1, and other 
inflammatory products is also suggested to have a role in the development of insulin 
resistance (see 1.4.1). 
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1.4 AT inflammation 
 
1.4.1 Link between obesity, inflammation and insulin resistance 
 
During the past decade, it has become clear that obesity, insulin resistance and type 2 
diabetes are closely associated with a state of chronic low-level inflammation. This is 
indicated by elevated plasma levels of C-reactive protein (CRP), IL-6 and PAI-1 in 
obese individuals (85-88). 
The first molecular link between inflammation and obesity was provided in 1993 by 
Hotamisligil et al who showed that the inflammatory cytokine TNFα is overexpressed 
in the adipose tissue of obese rodents. Neutralization of TNFα led to a decrease in 
insulin resistance in these models of obesity (54).  Later, TNFα overproduction of AT 
was also confirmed in obese humans, demonstrating the importance of this cytokine to 
obesity and insulin resistance (42, 89).  
By now it is widely accepted that the adipose tissue acts as an endocrine organ by the 
secretion of cytokines and other bioactive substances, including Mcp-1, PAI-1, IL-6, 
resistin, and adiponectin, some of which directly decrease insulin sensitivity (34, 49, 57, 
80, 90, 91). Moreover, it has been found several years ago that macrophages accumulate 
in obese white adipose tissue and that macrophages are the major producers of 
inflammatory mediators. This suggests a potentially important influence of  AT 
macrophages in promoting insulin resistance (34, 60).  
 Nevertheless, it has remained unclear how inflammation in adipose tissue is 
initiated. It is assumed that the process is started in the adipocytes in which dietary 
excess and obesity cause lipid accumulation and cellular stress (80) (ROS (92, 93) and 
ER stress (94-96)) that lead to activation of  the inflammatory signaling pathways of 
JNK (97, 98) and IKKβ/Nf-κB (99, 100) (Figure 3).  
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Figure 3. Potential cellular mechanisms for activating inflammatory signaling (80) 
 
Obesity-induced IKKβ activation leads to NF-κB translocation and the increased 
expression of numerous inflammatory markers that may cause insulin resistance. JNK 
activation promotes phosphorylation of IRS-1 at serine residues that impairs 
downstream insulin signaling events, thereby promoting an insulin resistant state. 
Moreover, these inflammatory signaling pathways lead to increased adipocyte 
production of cytokines, including TNFα, IL-6 and chemokines such as Mcp-1 that 
attract monocytes into the adipose tissue where they differentiate into macrophages. The 
differentiated macrophages produce many of the same inflammatory cytokines and 
chemokines including but not limited to those listed above, to further promote and 
propagate the inflammatory response that ultimately results in insulin resistance (80).  
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1.4.2 Adipose tissue macrophages (ATMs) 
 
1.4.2.1 Macrophages 
Macrophages are phagocytic cells of the innate immune system and originate from 
myeloid progenitor cells in the bone marrow. They are distributed widely in the body 
tissues, where they play a critical part in innate immunity. Macrophages mature from 
monocytes, which circulate in the blood and differentiate into macrophages upon 
migration into tissues. Macrophages are the primary mediators of the innate immune 
response and also participate in adaptive immunity. They recognize and phagocytose 
foreign organisms, as well as dead cells and cell debris, release antimicrobial peptides, 
secrete molecules that attract other immune cells to areas of infection, and present 
antigens to lymphocytes. Macrophages express different receptors that recognize 
bacterial molecules and mediate the adhesion to other immune cells, endothelial cells 
and matrix proteins, such as CD14, the mannose receptor (MR), the scavenger receptor, 
the glucan receptor, the adhesion molecules CD44 and CD31, and the integrin chains 
CD11a, CD11b, and CD11c (101, 102). 
 
1.4.2.2 Macrophage activation 
According to the classical view, macrophages are stimulated by interferon-(IFN)γ alone 
or in combination with a microbial stimulus. IFNγ is produced by CD4+ Th1 cells, 
CD8+ T-cells, and natural killer cells in order to activate macrophages in innate and 
adaptive immune responses. Activated macrophages produce inflammatory cytokines 
(IL-1, TNFα, IL-6), reactive oxygen and nitrogen intermediates to kill the pathogens 
and are capable of inducing Th1-polarized T-cell responses (102). These classical 
macrophages are named M1. 
Less well defined is the alternative activation of macrophages by IL-4 and IL-13, 
particularly in allergic, cellular and humoral responses to parasitic and extracellular 
pathogens (103). Macrophages activated that way are referred to as M2 and are 
characterized by an upregulated expression of anti-inflammatory cytokines IL-1 
receptor agonist and IL-10 leading to downregulation of inflammatory processes (104-
107). They promote Th2 responses and accordingly exert poor anti-bacterial killing 
activity, but are highly active in particle uptake, which is reflected by expression of the 
non-opsonic pathogen receptors MR (CD206) (108) and the β-glucan receptor (109). 
Importantly, M1 and M2 macrophages as used in this thesis are regarded as only two 
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extremes of a continuum of functional stages of macrophages (103).  
 
1.4.2.3 ATM infiltration in obesity and insulin resistance 
Inflammatory cytokines are highly expressed in obese AT and promote the development 
of insulin resistance. Several lines of evidence have demonstrated that the main source 
of inflammatory adipokine (1.4.1) production in AT are nonfat cells, such as 
macrophages, that infiltrate the adipose tissue directly proportional to measures of 
adiposity (60, 110).  
It is supposed that macrophages are recruited by chemotactic signals, such as Mcp-1, 
produced by the expanding adipocytes (82). Morphological examination of obese AT 
has revealed that macrophages localize around necrotic adipocytes, where they form so-
called crown-like structures that probably sequester adipocyte debris (111). ATMs are 
therefore supposed to have clearance purposes, yet they may also reflect an attempt to 
limit the expansion of the adipocytes (10).  
In vitro studies have shown that macrophage-secreted factors affect insulin sensitivity in 
adipocytes by altering expression of the glucose transport protein 4 (GLUT4) and IRS-1 
in 3T3-L1 adipocytes (112, 113) and inhibit adipogeneses of preadipocytes (114). These 
findings suggest that ATMs critically contribute to the development of insulin 
resistance but their exact role in this process has not been fully delineated yet. 
 
1.4.2.4 The nature of ATMs 
Most experimental data on AT inflammation stem from murine experiments and in 
general, F4/80 expressing cells in murine AT are referred to as ATMs. Moreover, 
murine ATMs have been shown to be CD14 negative and CD11c has been found 
particularly as a marker for obesity-induced inflammatory (M1) ATMs (115, 116). 
Human ATMs markedly differ from murine ATMs by expressing CD14 whereas 
CD11c is only poorly expressed (115, 117, 118).  
In a recent study of our lab, human ATMs were found to resemble M2 macrophages 
phenotypically by the expression of characteristical M2 surface markers (MR, CD163, 
integrin αvβ5), their endocytic activity and the production of anti-inflammatory 
cytokines (IL-10, IL-1 receptor antagonist). By contrast, ATMs were also capable of 
secreting large amounts of inflammatory cytokines that are supposed to interfere with 
adipocyte function but the exact mechanisms leading to obesity-related diseases are not 
fully elucidated yet (118).  
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1.5 Osteopontin (OPN)  
 
 
 
 
 
 
 
 
 
Figure 4. Some features of the OPN protein. Sites of O-glycosylation and phosphorylation are indicated; 
both vary (phosphorylation in particular) with the source of the protein. Numbering of the amino acids is 
based on the human protein (119). 
 
1.5.1 Functions of Osteopontin 
 
Osteopontin (Figure 4), also called secreted phosphoprotein 1 (SPP1) is a secreted 
matrix glycoprotein and inflammatory cytokine that has been implicated in a number of 
physiological and pathological events, including inflammatory processes (119). It is 
expressed by activated macrophages and T-cells, smooth muscle, endothelial, epithelial 
cells, and osteoclasts (120, 121). OPN was originally classified as Th1 cytokine and is 
involved in mineralization of bone and kidney, cell survival, tumor biology, and 
atherosclerosis (121, 122). It is secreted by macrophages at sites of inflammation and 
induces expression of inflammatory cytokines in peripheral blood mononuclear cells 
thereby playing a major role in cell-mediated immunity (123). It is known that OPN 
induces signaling pathways such as MEKK1/JNK1/AP-1 (124), IKK/IκB-α/NFκB 
(125, 126), and also FAK/PI(3)K/Akt (127). These data, however, have all been 
obtained from experiments in mice (tumor cells and pro-B-cells, respectively) and it 
was believed that some of these results may be due to LPS contamination of OPN 
preparations (128). 
  Its ability to interact with integrin surface receptors through an RGD sequence 
and with the CD44 receptor has established OPN as an important attachment and 
signaling molecule (119, 129, 130). It functions in cell migration, particularly of 
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monocytes/macrophages, and stimulates expression of matrix metalloproteases to 
induce matrix degradation and facilitate cell motility (120, 131, 132). Moreover, it is 
now well recognized that OPN plays a role in various inflammatory diseases, such as 
rheumatoid arthritis (133), atherosclerosis (134), and cardiac fibrosis (135). 
 
1.5.2 Osteopontin in obesity and insulin resistance 
 
Previous data from our group indicated considerable upregulation of the OPN gene spp1 
in the AT of obese mice and humans, and ATMs were found to be the main source of 
OPN production (131, 136). Further animal studies by us and others revealed improved 
insulin sensitivity of high-fat diet-induced OPN deficient mice and decreased AT 
inflammation without any effect on body mass or energy expenditure. Moreover, 
Nomiyama et al observed decreased ATM infiltration in these mice (129). These results 
strongly suggest a key role of OPN as a link of obesity and insulin resistance by 
promoting AT inflammation. 
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2 Aim of the study 
 
Obesity gives rise to a state of chronic low-grade inflammation that contributes to 
insulin resistance and type 2 diabetes. This inflammation is characterized by an 
increased infiltration of macrophages into AT along with production of inflammatory 
cytokines that are thought to play a major role in the origin of inflammation. 
 Animal experiments in our laboratory showed that the OPN gene, spp1, is 
exceptionally upregulated in the AT of high-fat diet-induced obese mice and that spp1 
knockout mice show improved insulin sensitivity. These results and the fact that OPN is 
mainly produced in activated macrophages point towards a potential role of OPN in 
obesity-associated inflammation and insulin resistance.  
 As a result, it is the aim of this thesis to elucidate the mechanisms by which 
OPN contributes to AT inflammation and insulin resistance. Here we investigate if and 
how OPN interacts with cells of the AT, ATMs and adipocytes. To address these 
questions, we make use of human model macrophages and ATMs, murine wt and spp1  
knockout ATMs, human and murine adipocytes as well as murine ATM/adipocyte 
coculture systems.  
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3 Materials and Methods 
 
3.1 Generation of human model macrophages 
 
3.1.1 Isolation of peripheral blood mononuclear cells (PBMCs)  
 
Buffy coats from healthy donors (obtained from LKH Graz) were diluted 1:1 with 
Dulbecco’s phosphate-buffered-saline (PBS; Cambrex). 15 ml Ficoll Paque Plus 
(Amersham Pharmacia) was placed in 50 ml tubes and 35 ml of diluted blood carefully 
placed on top. Tubes were centrifuged for 30 min (500 x g, RT, low brake) and the 
interphase containing mononuclear cells was collected, transferred into fresh 50 ml 
tubes, and washed twice with cold PBS at 500 x g, 7 min, 4 °C. Pellets were hemolysed 
in hemolysis buffer (0.15 M NH3Cl, 0.1 M KHCO3, 500 mM EDTA) for 7 min on ice 
and washed with PBS at 1,600 rpm, 7 min, 4 °C. Cells were resuspended and counted in 
35 ml MACS buffer (0.5% BSA, 125 mM EDTA in PBS). 
 
3.1.2 Separation of monocytes (CD14+ cells) by magnetic cell sorting 
 
Isolated PBMCs were washed twice in MACS buffer at 300 g, 10 min, 4 °C and 
resuspended in 800 µl MACS buffer and 200 µl CD14 microbeads (Miltenyi) per 
approx. 100 x 106 cells, mixed well and incubated on ice for 15 min. Samples were 
washed at 300 g,  10 min, 4 °C and resuspended in 500 µl MACS buffer per 100 x 106 
cells. LS columns (Miltenyi) were placed on the MACS seperator (quadro MACS, 
Miltenyi) and equilibrated with 3 ml MACS buffer. Samples were applied onto the 
column and washed three times with 3 ml MACS buffer. After removing the column 
from the seperator, the fraction containing the magnetically labeled CD14+ cells was 
immediately flushed out in 5 ml MACS buffer by firmly applying the plunger supplied 
with the column.    
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3.1.3 Macrophage differentiation 
 
In order to obtain model macrophages, M1 (IFNγ) and M2 (IL-4) macrophages were 
differentiated from CD14+ sorted PBMCs (monocytes). 2.5 x 106 cells per well of a 6-
well plate were cultivated in 4 ml RPMI 1640 with 50 µg/ml streptomycin, 50 U/ml 
penicillin (all invitrogen) and 10% fetal calf serum (FCS; Hyclone), supplemented with 
100 ng/ml IFNγ (Strathmann) or 10 ng/ml IL-4 (R&D Systems) to induce differentiation 
into M1 and M2 macrophages, respectively. Cells were kept in this medium for 5 days 
and thereafter used for experiments.   
 
3.2 Isolation of human ATMs 
 
3.2.1 AT fractionation 
 
Subcutaneous AT (abdomen) was obtained from patients undergoing reductional plastic 
surgery. Omental AT was obtained from organ donors. This study was approved by the 
ethics committee of the Medical University Vienna and the General Hospital Vienna. 
 Samples were repeatedly rinsed in PBS to remove any blood. Blood vessels, 
fibrous material and connective tissue were carefully dissected and AT was cut into 
pieces of approx. 5 x 5 mm. AT was transferred into 50 ml tubes (10 g per tube) with 25 
ml RPMI 1640 including Liberase Blendzyme 3 (Roche) at 35 µg/ml and DNase I 
(Sigma) at 50 U/ml and was incubated for 1 hour at 37 °C and 80 rpm. The digested 
tissue was passed through a 70 µm nylon mesh filter (Becton Dickinson, BD) and 
centrifuged at 1,000 x g, 10 min, 4 °C. Floating cells (adipocytes) and supernatants were 
removed. The pellet comprised the stromal vascular cell (SVC) fraction6. The SVC 
pellets were resuspended in 2 ml hemolysis buffer per tube and incubated on ice for 5 
minutes. Subsequently, 45 ml cold PBS was added, the suspension passed again through 
a 70 µm filter and centrifuged at 500 x g, 7 min, 4 °C.  
 
 
                                                 
6 The SV fraction is a mixed population of stromal cells comprising ∼ 40 – 60% macrophages, 
preadipocytes, fibroblasts, and endothelial cells. 
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3.2.2 ATM isolation by MACS 
 
Hemolysed pellets were resuspended in 1 ml Beriglobin (unspecific human antibodies, 
ZLB Behring, Vienna, Austria) per approximately 10 x 106 cells and cells were counted 
with a Bürker-Türk counting chamber. For flow cytometry-analysis, 100,000 – 200,000 
cells per sample were pipetted on ice into a 1.4 ml u-tube (Micronic). After 
centrifugation at 500 x g, 3 min, 4 °C the pellet was resuspended in 80 µl MACS buffer 
and 20 µl CD14 MicroBeads (Miltenyi) per 10 x 106 cells and incubated for 15 minutes 
on ice. Samples were washed twice with 1 ml MACS buffer and resuspended in 500 µl 
(up to 108 cells) MACS buffer. Magnetic cell sorting was performed as described in 
3.1.2 with the modification that MS columns were used which were equilibrated and 
washed with 500 µl MACS buffer. Cells were flushed out with 1 ml MACS buffer. To 
obtain higher purity the MACS-separation was repeated. Approximately 50,000 ATMs 
were used for flow cytometry-analysis to determine purity, which was 75 – 80 % CD14+ 
cells.  
 
3.2.3 ATM isolation by FACS 
 
Hemolysed SVC pellets were resuspended in 50 µl MACS buffer and 25 µl of FITC-
labeled CD14 and PE-labeled CD206 (MR) anti-human antibodies (both BD) per 10 x 
106 cells. Samples were incubated on ice for 45 minutes and washed in PBS at 300 x g, 
7 min, 4 °C. The Pellet was resuspended in 4 ml PBS, passed through a 70 µm filter and 
transferred into a FACS u-tube. Cells were sorted in FACSVantage or FACSAria (both 
BD) for CD14+MR+ and CD14+MR- and taken up in 3.5 ml of culture medium. Sorted 
cells were centrifuged at 300 g,  5 min, 4 °C and resuspended in 400 µl culture medium. 
Approximately 20 µl of samples prior and post sorting were analyzed in FACSCalibur 
(BD) for purity of isolated populations. For isolation of RNA, sedimented cells were 
taken up in 0.5 ml TRIzol Reagent (invitrogen) and stored at –20 °C.  
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3.3 Quantitation of cytokine secretion 
 
3.3.1 Cell stimulation 
 
ATMs, M1s and M2s were stimulated with OPN and, for comparison, other cytokines 
and cell-activators to quantify their cytokine secretion. IFNγ and TNFα were purchased 
from R&D systems, LPS and OPN from Sigma.  100,000 cells per well of a 96-well 
plate were incubated for 2 days (M1 and M2) or 3 days (ATMs) at 37 °C in 200 µl 
culture medium supplemented with cytokine concentrations indicated in the results 
section. Subsequently, cell free supernatants were collected and stored at -20 °C for 
analysis of cytokine and chemokine concentrations.  
 
3.3.2 Multiplexed microsphere-based flow cytometry 
 
Cell free supernatants of ATMs, M1 and M2 were assayed with Human Fluorokine 
MultiAnalyte Profiling Kits (R&D Systems) for IL-10, TNFα and Mcp-1 according to 
the manufacturer’s instruction. Briefly, 50 µl of the diluted microparticle mixture (6 x 
104 beads/ml in 1% BSA) were added to each well of the microplate. 50 µl of standard 
or sample per well were added. The assay was incubated on a horizontal orbital 
microplate shaker at 500 rpm, 3 h, RT. Subsequently, samples were washed 3 times 
with 100 µl PBS and 50 µl of diluted biotin-conjugated antibody cocktail was added to 
each well. Dilutions used were 1:250 for IL-10, 1:400 for TNFα and 1:100 for Mcp-1 in 
1% BSA. The plate was again incubated at 500 rpm, 1 h, RT and washed as described 
above. 50 µl of diluted streptavidin-PE [4 µl/ml in 1% BSA] was added to each well 
and the plate again incubated at 500 rpm, 30 min, RT and washed two times with PBS. 
The microparticles were resuspended by adding 90 µl PBS to each well and the assay 
was read by using a Luminex 100 ISTM analyzer.  
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3.4 Western Blot 
 
3.4.1 Stimulation and lysis of macrophages 
 
Differentiated M1 and M2 macrophages as described in 3.1.3 were harvested by using a 
scraper and centrifuged at 500 g, 7 min, 4 °C. Pellets were resuspended in culture 
medium to approximately 10 x 106 cells/ml and counted by using a Bürker-Türk 
counting chamber. Aliquots of 150 µl containing at least 0.5 x 106 cells were stimulated 
with 1 µg/ml OPN, 100 ng/ml LPS, or left untreated for indicated time periods on a 37 
°C waterbath. Cells were pelleted for 20 s and lysed in 50 µl lysis buffer for 30 minutes 
on ice (20 mM Tris/HCl pH 7.4, 140 mM NaCl, 1 % NP-40, 10 µg/ml aprotinin, 5 mM 
lodoacetamide, 10 µg/ml leupeptin, 1 µM pepstatin, 0.4 mM Pefabloc, 1 mM sodium 
orthovanadate, 10 mM NaF, 2.5 mM EDTA, 5 mM sodium pyrophosphate, 25 mM B-
glycerolphosphate). Samples were spun down for 30 s and supernatants mixed with 15 
µl 4 x sample buffer (240 mM Tris/HCl pH 6.8, 400 mM DTT, 8 % SDS, 44 % 
glycerol, 0.02 % Bromphenol-blue), heated at 99 °C for 3 minutes and stored at -20 °C.  
 
3.4.2 SDS-PAGE 
 
10 % acrylamidgels were made by injecting a 10% running gel solution (0.375 M 
Tris/HCl pH 8.8, 10% Acrylamid/Bis Solution (BioRad), 0.005 % APS, 0.004 % 
TEMED) into a BioTrade gel pouring chamber and overlaying it with 2-Butanol. 
Polymerized running gels were washed with water, dried by using a filter paper and 
overlaid by a 4 % stacking gel (0.125 M Tris/HCl pH 6.8, 4 % Acrylamid/Bis Solution, 
0.001% APS, 0.0008 % TEMED). 14-well combs were inserted into the stacking gel 
and removed when gels were polymerized. Gels were placed into a running chamber 
and covered with running buffer (25 mM Tris, 192 mM Glycine, 0.1 % SDS). Slots 
were loaded with 7 µl prestained Molecular weight marker (BioRad Broad Range, 6 – 
203 kDa) and 14 µl sample, respectively and gels were run at 130 V for 1.5 h.  
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3.4.3 Blot 
 
Proteins were blotted onto a nitrocellulose membrane (Amersham Hybond ECL) by a 
semi-dry blotting apparatus (C.B.S. apparatus, BioTrade) for approximately 1 hour at 
maximally 23 V, limited to 0.1 A/gel. Ponceau Red staining was performed in order to 
verify successful operations and uniform protein concentrations in samples.  
Blots were analyzed by use of a BM Chemiluminescence Blotting Substrate (POD) Kit 
(Roche). Briefly, membranes were blocked for 1 h in a 1:5 dilution of blocking reagent, 
washed twice in TBS-T (0.05 M Tris, 0.14 M NaCl, 0.05 % Tween, pH 7.5) and 
incubated with primary antibodies O/N at 4 °C. The following day, blots were washed 
as described above, blocked for another 10 min and incubated with secondary HRP-
conjugated antibodies for 45 minutes RT protected from light. Thereafter, blots were 
washed three times with TBS-T and covered with substrate (1:100 dilution of 
Luminescence starting solution B in substrate solution A) for 2 minutes. 
Chemiluminescence was measured by a Lumi Imager (Roche; exposure time 10 
minutes). Following antibodies and dilutions were used: IRAK-1 (Santa Cruz,  rabbit 
anti-human, 1:100), IκB-α (Calbiochem, rabbit anti-human, 1:500), p-ERK (Santa 
Cruz, mouse anti-human, 1:500), ERK-2 (Santa Cruz, mouse anti-human, 1:2,000) p-
Akt (Biovision, rabbit anti-human, 1:500), Akt (Biovision, rabbit anti-human, 1:500), p-
p38 (Cell Signaling, rabbit anti-human, 1:500), p38 (Santa Cruz, mouse anti-human, 
1:500), pJNK (New England Biolabs, rabbit anti-human, 1:500), goat anti-rabbit-HRP-
conjugated secondary antibody (Accurate, 1:10,000), goat anti-mouse-HRP-conjugated 
secondary antibody (Biorad, 1:3,000). 
 
3.5 Intracellular staining of MAP Kinase phosphorylation 
 
Differentiated M1 macrophages were harvested and stimulated with OPN or LPS as 
described in 3.4.1. After incubation at 37 °C, the reaction was stopped with cold PBS. 
Samples were spun down for 20 s at 4 °C and supernatants removed.  Cells were fixed 
and permeabilized using a Fix & Perm Cell Permeabilization Kit (An der Grub). 
Briefly, cells were fixed in 100 µl solution A for 15 min at RT and washed twice with 
PBS at 1,800 rpm, 3 min, RT. Subsequently, 50 µl permeabilization solution B and 1 µl 
primary antibody were added and samples incubated for 30 min at RT. Cells were 
washed twice with MACS buffer as described above  and incubated in 20 µl of stained 
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secondary antibody dilution. After the incubation time of 30 min at RT, cells were 
washed with MACS buffer and PBS and resuspended in 200 µl PBS. Samples were 
analyzed in FACSCanto II (BD). 
Following antibodies were used: rabbit anti-human p-JNK (Cell Signaling), secondary 
AlexaF488-conjugated goat-anti-rabbit IgG (invitrogen, 1:400 dilution). All obtained 
values were corrected for background fluorescence by staining with secondary antibody 
only.  
 
 
 
3.6 Analysis of murine ATMs 
 
3.6.1 Animals and animal care 
 
To stimulate diet-induced obesity, male C57BL/6J wt or OPN-/- (spp1) mice (Charles 
River Laboratories, Sulzfeld, Germany) aged 7 weeks were placed on a high-fat diet (60 
kcal percent fat, D12450B, Research Diets Inc., New Brunswick, NJ) for 20 weeks. 
Mice kept on a low-fat diet (10 kcal percent fat, D12492, Research Diets Inc.) served as 
lean controls. Animals had free access to food and water and were maintained on a 12-h 
light, 12-h dark cycle. After 20 weeks on the diet, mice were killed by cervical 
dislocation. The study protocols were approved by the local ethics committee for animal 
experiments, and followed the guidelines on accomodation and care of animals 
formulated by the European Convention for the Protection of Vertebrate Animals Used 
for Experimental and Other Scientific Purposes.  
 
3.6.2 ATM isolation and FACS analysis 
 
Epididymal fat pads from male C57BL/6J wt or spp1 knockout mice fed a LFD or HFD 
were excised and minced in 5 x 5 mm pieces. 0.5 g tissue/ml was digested with 35 
µg/ml Liberase Blendzyme 3 (Roche) and 50 U/ml DNase I (Sigma) in RPMI 1640 for 
45 min at 37 °C, 80 rpm. Digested tissues were passed through 250 µm mesh filters. 
After centrifugation at 1,000 x g, 7 min, 4 °C, the stromal vascular pellets wer lyzed in 
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1 ml of hemolysis buffer and remaining cells passed through a 70 µm filter and 
centrifuged at 500 x g, 3 min, 4 °C.  For flow cytometry analysis, pellets were 
resuspended in Beriglobin to block Fc-receptors and stained for 45 minutes on ice 
protected from light. Following antibodies were used: CD44-PE-Cy5 (BD), F4/80-FITC 
(AbD Serotec), CD11c-APC (BD), CD206-Alexa488 (AbD Serotec), CD51-PE (BD), 
all as a 1:30 dilution in Beriglobin.  Cells were washed in PBS at 500 x g, 3 min, 4 °C 
and resuspended in 200 µl PBS.  Samples were analyzed in FACSCalibur (BD).  
 
 
 
3.7 Adipocyte cell culture 
 
3.7.1 3T3-L1 
 
3T3-L1 adipocytes were generated as described previously (137). 
3T3-L1 fibroblasts were generously provided by Karsten Kristiansen, Denmark. Cells 
were cultured in DMEM (invitrogen) containing 4,500 mg/l glucose, 110 mg/l sodium 
pyruvate, 4 µg/ml pantothenate supplemented with 2 mM L-Glutamine, 50 µg/ml 
streptomycin, 50 U/ml penicillin (all invitrogen), 4 µg/ml pantothenate and 8 µg/ml 
biotin (both Sigma). Standard proliferation medium contained 10% bovine calf serum 
(invitrogen) and cells were maintained at less than 30% confluence. Differentiation of 
3T3-L1 cells into adipocytes was induced by exposing 2-3 d postconfluent (designated 
day 0) cells to DMEM containing 10% FBS (invitrogen) supplemented with 500 nM 
dexamethasone, 500 µM IBMX, and 1 µg/ml insulin from bovine pancreas (all Sigma). 
At Day 2, cells were fed DMEM containing 10% FBS and 1 µg/ml insulin; after another 
2-4 days cells were kept in DMEM and 10% FBS. Adipocytes were used in experiments 
at Day 8 – 10 of differentiation.  
 
3.7.2 Generation of human adipocytes 
 
3.7.2.1 AT fractionation and preadipocyte isolation 
Subcutaneous AT was obtained from patients undergoing reductive plastic surgery 
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(abdomen and 1 back). Basically, stromal vascular cells containing preadipocytes were 
isolated as described in 3.2.1 with some modifications: Minced AT was digested in a 
solution of 2 mg/ml Collagenase Type IV in Hanks’ buffered salt solution (HBSS, both 
Sigma), 0.01 M HEPES supplemented with 50 µg/ml streptomycin, 50 U/ml penicillin 
(both invitrogen) and 25 µg/ml amphotericin B (Sigma). Tissue was digested as 
described and filtered through a 250 µm nylon mesh. The cell suspension was 
centrifuged at 200 x g, 10 min, 4 °C. Erythrocytes were hemolysed as above and SVCs 
were pelleted at 300 x g, 7 min, 4 °C.  Cells were resuspended in DMEM/Ham’s-F12 
medium (Sigma, including 15 mM sodium carbonate and 15 mM HEPES) 
supplemented with 20% FCS (Hyclone), 50 µg/ml streptomycin, 50 U/ml penicillin and 
25 µg/ml amphotericin B, referred to as proliferation medium. 
 
 
 
3.7.2.2 Culture and differentiation of preadipocytes 
Human preadipocytes were generated as described previously (138) with some 
modifications: Stromal vascular cells were seeded at a density of 100,000/cm2 in 12-
well plates (Corning Costar, CellBIND surface), each well representing ∼ 4.5 cm2. After 
16 – 20 h routinely used for cell attachment, cells were carefully washed with PBS to 
remove nonadhering material, mainly white blood cells and cell debris, and fed with 
proliferation medium. Preadipocytes were grown to confluence for a maximum of 4 
days, then washed twice with PBS to remove any serum that may interfere with 
differentiation. To induce differentiation of preadipocytes, cells were incubated in a 
chemically defined serum-free medium consisting of DMEM/Ham’s F-12, 33 µM 
biotin, 17 µM pantothenate, 1 nM triiodothyronine, 100 nM dexamethasone (all Sigma), 
500 nM human insulin (Roche), 1 µM rosiglitazone (generously provided by Johnson & 
Johnson), and, for the first 3 days, 250 µM IBMX (Sigma). To investigate a putative 
effect of OPN on preadipocyte differentiation, 500 nM OPN was added to the 
differentiation medium. Half of the medium was changed every 2 days and cells were 
used for experiments at day 9 – 11 of differentiation (Figure 5). 2 days prior to the 
experiment (glucose uptake), dexamethasone, insulin, and rosiglitazone were removed 
from the medium.  
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Figure 5. Morphology of human adipocytes differentiated for 14 days in culture. 
 
3.7.3 Coculture of macrophages and adipocytes 
 
Murine SVC from C57Bl/6J wt or spp1 fed a HFD or LFD were isolated as described in 
3.6.2. Cells were resuspended in growth medium at a concentration of approximately 
100,000 cells/ml. Cells were allowed to attach on 12-well cell culture inserts (BD, pore 
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size 0.4 µm) at a concentration of 100,000 cells/well for 2 h at 37 °C. Nonadherent cells 
were washed away with PBS and inserts were added to differentiated 3T3-L1 
adipocytes (6 – 8 days after induction of differentiation) for 48 h prior to the 
experiment.  
 
3.7.4 2-Deoxyglucose uptake assay 
 
3.7.4.1 3T3-L1 
To investigate the effect of OPN and other substances on insulin sensitivity, 
differentiated 3T3-L1 adipocytes were pretreated with concentrations indicated in the 
results section 48 h prior to the assay. During the last 12-14 hours of the treatment (over 
night), cells were starved in serum-free DMEM 1,000 mg/l glucose supplemented with 
0.5% BSA, 50 µg/ml streptomycin and 50 U/ml penicillin (starving medium) before 
insulin stimulation. In case of macrophage/adipocyte coculture, inserts were removed 
and adipocytes were starved in starving medium 3 h prior to insulin stimulation without 
OPN-treatment. After the starving period, cells were washed twice with Krebs-Ringer-
Phosphate-HEPES (KRPH) buffer (136 mM NaCl, 5 mM Sodium phosphate buffer pH 
7.4, 20 mM HEPES, 4.7 mM KCl, 1 mM MgSO4, 1 mM CaCl2) and incubated with or 
without 1 µM insulin from bovine pancreas (Sigma) in 0.5 ml KRPH buffer for 30 min 
at RT. Subsequently, 1 µCi [3H]2-deoxyglucose (Amersham Pharmacia) was added to 
all wells, i.e. 25 µl of a 20 µCi/ml stock solution  and incubated for 10 min at RT. The 
[3H]2-deoxyglucose stock solution was supplemented with 1 mM 2-deoxyglucose 
(Sigma) to provide glucose concentrations of 50 µM during the reaction. Glucose 
uptake was terminated by three washes with ice-cold PBS and the cells were lysed in 
500 µl 0.2 N NaOH. 300 µl cell lysate were added to a scintillation vial containing 4 ml 
Ultima Gold High Flash Point LSC-cocktail (Perkin Elmer) and radioactivity was 
measured by a beta scintillation counter. To determine the total counts per minute, 2 µl 
of [3H]2-deoxyglucose stock solution were mixed with 4 ml LSC-cocktail and 
radioactivity was counted.  
Protein concentrations of the lysates were determined by a BCA Protein Assay Kit 
(Pierce) with BSA as the standard and data was expressed as pmol radioactive glucose 
taken up per 5 minutes and per mg protein (pmol/5 min/mg protein).  
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3.7.4.2 Human adipocytes 
The glucose uptake assay was performed essentially as in 3.7.4.1 with the modification 
that adipocytes were not starved, and 1 µM human insulin was added directly to 0.5 ml 
medium and incubated for 15 min at 37 °C. Since glucose was already present in the 
medium, the [3H]2-deoxyglucose stock solution was not supplemented with 2-
deoxyglucose. Cells were incubated with 1 µCi [3H]2-deoxyglucose for 20 min at 37 
°C, washed and lysed as described above. 
3.8 Gene expression analysis 
 
3.8.1 RNA isolation 
 
Human adipocytes at day 10 of differentiation were harvested in 1 ml Trizol, human 
ATMs as described in 3.2.3 were resuspended in 0.5 ml Trizol and both stored at -20 
°C. RNA was isolated according to the manufacturer’s protocol: 500 µl sample were 
transferred into Phase Lock Gel Heavy Tubes (Eppendorf Austria), mixed with 100 µl 
chloroform and 120 µl RNase-free water and incubated for 10 minutes at RT. Samples 
were centrifuged at 13,000 rpm, 15 min, 4 °C, and 380 µl of the RNA-containing 
aqueous phase was transferred into fresh tubes. 1 µl GlycoBlue (Ambion) was added to 
each sample and RNA was precipitated with 280 µl cold isopropanol for 30 min on ice. 
Samples were centrifuged at 13,000 rpm, 30 min, 4 °C. The RNA pellets were washed 
twice with 75% RNase-free ethanol at 10,000 rpm, 5 min, 4 °C, dried and dissolved in 
22 µl RNase-free water. 
 
3.8.2 cDNA synthesis 
 
22 µl of isolated RNA (∼ 1 µg) were mixed with 17 µl PCR mastermix containing First 
Strand Buffer, 12.5 mM DTT, 625 µM dNTPs, 187.5 ng/µl Random Hexamers and 50 
U RNase Out Ribonuclease Inhibitor (all invitrogen). RNA secondary structure was 
denaturated for 15 minutes at 65 °C. Thereafter, 200 U of Super Script II Reverse 
Transcriptase (invitrogen) were added to the reaction and RNA was reverse transcribed 
into cDNA by 10 min of primer annealing at 25 °C and 50 minutes of reverse 
transcription at 42 °C. Finally,  the reaction was heated at 70 °C for 15 minutes to 
inactivate the enzyme.  
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3.8.3 Quantitative Real-Time PCR (RT-qPCR) 
 
RNA expression was quantified by RT-qPCR using an ABI Prism 7000 cycler (Applied 
Biosystems) and commercial Assay-on-demand kits for human TNFα, spp1, IL-10, 
CCL-2 (Mcp-1), SLC2A4 (GLUT-4), PPARγ, LIPE, and adiponectin (all Applied 
Biosystems) according to the manufacturer’s protocol.  Each PCR reaction contained, in 
a final volume of 25 µl, 0.625 µl of first-strand cDNA, 12.5 µl 2 x TaqMan Universal 
PCR Master Mix, 1.25 µl 20 x TaqMan Gene Expression Assay (both Applied 
Biosystems) and 10.625 µl H2O. All reactions were performed using the following 
cycling conditions: 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles at 95 °C 
for 15 s, and 60 °C for 1 min. PCR was carried out in duplicates in MicroAmp Reaction 
Optical 96-well plates (Applied Biosystems). Target gene mRNA expression was 
normalized to 18S rRNA and the relative amounts of all mRNAs were calculated using 
the comparative ∆CT method. 
 
3.9 Statistics 
 
All values are given in mean ± SE. Significance of differences between two groups 
were assessed by the unpaired Student’s t test. For analyses of more than two groups, 
One-way Anova and post-hoc Dunnett tests were used.  P < 0.05 was considered as 
statistically significant. 
 
 
 35 
4 Results 
 
4.1 OPN-induced macrophage activation 
 
4.1.1 OPN stimulates signal transduction in M1 macrophages 
 
As described in 1.4.2.2, we used classical M1 as well as alternatively activated M2 
macrophages as model ATMs. To investigate a putative effect of OPN on the activation 
of signaling pathways in macrophages, M1 were stimulated with OPN and, for 
comparison, LPS for 15’, 30’, and 60’. Data for M2 macrophages is omitted because no 
activation of signaling pathways was detected upon LPS stimulation. After 15 minutes 
of stimulation, IRAK-1 is degraded if activated by LPS, but not OPN, thereby 
indicating that OPN signals independently from the LPS/TLR4/IRAK pathway. In 
contrast, OPN induced phosphorylation of the MAP Kinases p38 and ERK-2, as well as 
Akt and, to a minor extent, degradation of IκB-α (Figure 2). Interestingly, OPN-induced 
activation of signaling pathways was delayed in comparison to LPS, but reached, and in 
case of pERK even exceeded the strength of LPS-induced events after 60 minutes of 
stimulation.  Phosphorylation of JNK was strongly induced by LPS after 15 minutes of 
stimulation, but only weakly in OPN-stimulated cells (Figure 6).  
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Figure 6. OPN induces signal transduction in macrophages. M1 macrophages were treated with 1 µg/ml 
OPN (O), 100 ng/ml LPS (L), or left untreated for indicated time periods. Cell lysates were prepared and 
immunoblots probed with antibodies against respective proteins, ERK-2 as loading control. A 
representative experiment out of three is shown. 
 
To further verify this observation, we measured JNK phosphorylation by intracellular 
staining and flow cytometry.  As shown in Figure 7, LPS led to a 2-fold increase of 
pJNK-positive cells (unstimulated: 14.9% ± 2.5%; 15’ stimulated: 32% ± 3.1%, P = 
0.004). OPN did not lead to a profound increase in pJNK-positive cells (21.2% ± 3.8%), 
thereby indicating, consistent with Western Blot results, that OPN does not significantly 
activate the JNK/c-JUN pathway in macrophages. 
In summary, these data suggest that OPN is activating MAP Kinase pathways and the 
Akt pathway, as well as the NfκB pathway to a minor extent in human macrophages.  
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Figure 7. Phosphorylation of JNK in M1 macrophages. Cells were stimulated with 1 µg/ml OPN, 100 
ng/ml LPS, for indicated time periods, or left untreated, fixed and permeabilized and stained 
intracellularly for pJNK. Activation of pJNK was assessed by flow cytometry and depicted as percentage 
of pJNK-positive cells (n=13). Data are presented as mean ± SE. **P < 0.01 vs unstimulated. 
 
4.1.2 OPN-induced cytokine production of M1 and M2 macrophages 
 
ATMs are of M2-like phenotype, hence in our experiments we are using M2 (IL-4-
induced) macrophages as a model for ATM cytokine production in addition to 
conventional M1. Preliminary experiments had shown that LPS activation of M2 leads 
to production of substantial amounts of the anti-inflammatory cytokine IL-10 and the 
chemokine monocyte chemoattractant protein-1 (Mcp-1), which is implicated in 
inflammatory processes of obese AT.  In contrast, stimulation with OPN led to the 
production of high amounts of the inflammatory Mcp-1 but did not induce the anti-
inflammatory IL-10.  
To investigate concentration-dependent effects and putative interactions of OPN with 
LPS-induced activation, we stimulated M1 and M2 macrophages with indicated 
combinations of OPN and LPS concentrations. After 2 days, Mcp-1, IL-10 and TNFα 
concentrations in the supernatants were measured. In M2 macrophages, OPN induced 
moderate TNFα production in a concentration-dependent manner (130.5 ± 74 pg/ml, 
Figure 8a), whereas essentially no IL-10 and high amounts of Mcp-1 (6968.7 ± 2119.7 
pg/ml, P = 0.026, Figure 8b,c) were produced. However, neither an enhancement of 
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LPS-induced inflammatory cytokine production nor a suppression of LPS-induced anti-
inflammatory reactions was observed.  
 
 
Figure 8. OPN-induced cytokine production of M2 macrophages. M2 were stimulated with indicated 
concentrations (ng/ml) of OPN and LPS for 2 days and TNFα (a), Mcp-1 (b), and IL-10 (c) 
concentrations in the supernatants were measured. Diagrams show the mean concentrations of 2 donors. 
*P < 0.05 compared to untreated. 
 
In M1 macrophages, Mcp-1 production was similar to M2 (20,178 ± 3,114.5 pg/ml P = 
0,009, Figure 9b). TNFα was only induced by the highest concentration of OPN alone 
(419.1 ± 132.4 pg/ml, P = 0.038), but LPS-induced TNFα production was further 
enhanced by OPN (LPS: 922.794 ± 299 pg/ml; LPS+OPN: 1,271 ± 436 pg/ml, Figure 
9a). In contrast to the results obtained for M2, OPN was able to induce IL-10 production 
in M1 synergistically with LPS (OPN: 121 ± 43 pg/ml; OPN+LPS: 289 ± 76 pg/ml, 
Figure 9c).   
These data indicate that OPN is able to induce pro- and anti-inflammatory cytokine 
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production in human macrophages, whereas the exact pattern of secreted cytokines 
depends on the particular model system.  
 
 
 
 
Figure 9. OPN-induced cytokine production of M1 macrophages. M1 were stimulated with indicated 
concentrations (ng/ml) of OPN and LPS for 2 days and Mcp-1 (a), TNFα (b) and IL-10 (c) concentrations 
in the supernatants were measured. Diagrams show the mean concentrations of 2 donors. *P < 0.05, **P 
< 0.01 compared to untreated. 
 
 
4.1.3 Cytokine secretion of human ATMs 
 
4.1.3.1 Cytokine production of magnetically sorted CD14+ AT-SVC 
ATMs have been characterized by the expression of CD14 and MR on their surface 
(118) and several lines of evidence previously suggested that CD14+MR- cells prepared 
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from AT indicate contamination with blood monocytes probably from microvessels. 
Here, we isolated CD14+ cells from human adipose tissue via magnetic cell sorting, 
which is a fast and easy procedure but yields a cell population containing a considerable 
number of blood monocytes (∼20% of the total CD14+ population, data not shown). To 
determine the inflammatory mediator secretion pattern of ATMs, we stimulated CD14+  
cells from subcutaneous AT with OPN,  LPS, or IFNγ and analyzed cytokine secretion 
into the culture medium and also the CD14-depleted SVC (dSVC) fraction was included 
in this analysis. The investigated cytokines except Mcp-1 (601 ± 399.1 pg/ml) were not 
produced by the dSVC fraction in significant amounts. Therefore, production of the 
other cytokines by CD14- cells can be disregarded. We observed that CD14+  cell 
preparations produced large amounts of TNFα (390 ± 77 pg/ml) and Mcp-1 (1,141 ± 
111 pg/ml) and moderate amounts of the anti-inflammatory IL-10 (199 ± 82 pg/ml). 
Basal expression of all cytokines was markedly higher than in M1 and M2 model 
macrophages. Remarkably, CD14+ cells were only weakly stimulated by LPS, but 
responded to IFNγ with increased TNFα (968 ± 310 pg/ml) and Mcp-1 (2580 ± 559 
pg/ml) secretion. Moreover, cells did essentially not respond to OPN, except for a 
moderate increase in Mcp-1 production (2005 ± 1092 pg/ml), whereas a possible 
contribution of contaminating CD14- cells thereto cannot be excluded (Figure 10).  
 
 
 
 
 
 
 
Figure 10. Cytokine production of CD14+ 
cells. SVC from human AT were 
magnetically sorted for CD14+ (ATMs, 
black bars) and CD14- (= dSVC, grey bars; 
n=2). Cells were cultivated and stimulated 
with 1 µg/ml OPN, 100 ng/ml IFNγ, 100 
ng/ml LPS, or left untreated (med). *P < 
0.05; **P < 0.01 compared to dSVC. 
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4.1.3.2 Cytokine expression of CD14+MR+ ATMs 
Since magnetically sorted CD14+ ATMs are contaminated with blood monocytes, we 
used flow cytometry to separate CD14+MR+ ATMs from CD14+MR- cells. This 
procedure provided not only another method of ATM purification, but also enabled us 
to detect potential cytokine production of CD14+MR- cells that may contribute to the 
results obtained for magnetically sorted CD14+ cells.  
The initial populations usually  contained ∼ 4% CD14+MR- and ∼ 15% CD14+MR+ 
cells. Sorted populations had approximately 75% purity, the other 25% predominantly 
consisting of CD14- cells and cell fragments that may not disturb cultivation 
experiments (Figure 11).   
 
 
Figure 11. Isolation of CD14+MR* ATMs. AT SVC were stained with CD14-FITC and MR-PE 
antibodies and sorted by FACS. Cell populations prior (top) and post (bottom) sorting are shown in a 
representative dot blot.  
 
 
Isolated MR+ and MR- cells were cultured separately and treated with OPN, IFNγ, LPS, 
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or left untreated. As shown in Figure 12, basal concentration of Mcp-1 was similar to 
CD14+ cells (932 ± 31.4 pg/ml) whereas IL-10 and TNFα were hardly detected in 
untreated FACS-sorted ATMs. Remarkably, basal cytokine concentrations were equal 
in MR+ and MR- cells and both populations did not respond to IFNγ treatment, which is 
conflicting with the results obtained for CD14+ cells. Moreover, both OPN and LPS 
induced moderate IL-10 (OPN: 749 ± 245 pg/ml; LPS: 491 ± 167 pg/ml) and TNFα 
production (OPN: 39 ± 1 pg/ml, P < 0.001; LPS: 27 ± 2.6 pg/ml, P = 0.001) and Mcp-1 
was not induced by any of the substances except OPN in MR- cells only (4,413 ± 3,586 
pg/ml).  
These results suggest that contaminating CD14+MR- monocytes are also capable of 
cytokine production and may be activated further, which should be considered when 
investigating CD14+ magnetically sorted cells. However, there were profound 
differences in activation capacity and cytokine expression patterns of ATMs isolated by 
either MACS or FACS. 
 
Figure 12. Cytokine production of ATMs. Human SVC were stained for CD14 and MR and sorted by 
FACS into a CD14+MR+ (black bars) and a CD14+MR- (grey bars) population (n=2). Both populations 
were cultivated and stimulated with 1 µg/ml OPN, 100 ng/ml IFNγ, 100 ng/ml LPS, or left unstimulated 
(med). After 3 days, concentrations of indicated cytokines were measured in the supernatants. Data are 
presented as mean ± SE. **P < 0.01, ***P < 0.001 versus medium; #P < 0.05 versus MR-. 
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4.1.4 Gene expression of human ATMs 
 
Several lines of evidence suggest that in humans, only CD14+MR+ cells can be referred 
to as ATMs (118). OPN is an inflammatory cytokine that is extensively produced by 
activated macrophages (119). Thus, we hypothesized that predominantly CD14+MR+ 
cells mediate inflammatory cytokine production, including OPN, of the adipose tissue. 
Nevertheless, evidence to support this theory has been lacking so far and a potential role 
of CD14+MR- cells in AT inflammation cannot be excluded, either. Therefore, we 
isolated CD14+MR+ and CD14+MR- populations from human subcutaneous (n = 3) and 
omental (n = 6) AT SVC and examined cytokine and OPN gene expression by RT-
qPCR. We observed that all of the investigated cytokines, including OPN, IL-10, Mcp-
1, and TNFα where significantly higher expressed in MR+ compared to MR- cells 
(OPN: 8-fold increase, P = 0,042; IL-10: 2-fold increase, P = 0,0097; Mcp-1: 6-fold 
increase, P = 0,016; TNFα: 4-fold increase, P =0,018; Figure 13). These data indicate 
that human CD14+MR+ ATMs are capable of excessive OPN and inflammatory 
cytokine production, thereby confirming that MR+ and not MR- cells predominantly 
contribute to obesity-related AT inflammation. 
 
 
 
 
 
 
 
 
Figure 13. Gene expression of human ATMs. Human SVC were sorted into a CD14+MR+ (black bars, 
n=9) and a CD14+MR- (grey bars, n=9) population, and mRNA levels of indicated genes were measured 
by RT-qPCR. Gene expression levels were compared to the MR- population, which was designated as 
100%. Data are presented as mean ± SE. *P < 0.05, **P < 0.01 compared to MR-. 
 
4.1.5 ATM surface markers are not altered in spp1 knockout mice 
 
Preliminary experiments of our group revealed no significant difference in ATM 
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number between wt and spp1 knockout mice. We therefore aimed to investigate whether 
OPN deficiency has an influence on the activation state of ATMs by characterizing the 
expression of the ATM activation marker CD11c (116), the M2 marker MR and 
additionally, the OPN receptors CD51 and CD44 in wt and spp1 knockout ATMs. 
Epididymal fat tissue plays a significant role in overall metabolism in rodents (139). We 
thus isolated SVC from epididymal fat pads excised from male spp1 knockout or wt 
mice fed a LFD or HFD and analyzed cells by flow cytometry. Investigated surface 
markers included F4/80, and, as mentioned above, CD11c, MR, and the putative OPN 
receptors CD51 and CD44. F4/80 has been used by most previous studies as a single 
marker to identify murine ATMs. As expected, we observed an increase of F4/80+ cells 
in HFD mice (26.1% ± 1.3%  of SVC) compared to LFD mice (17% ± 2.7% of SVC), 
and correlating with our previous observation there was no difference between the wt 
and the spp1 genotype (spp1: 26.4% ± 2.5% HFD; 19.3% ± 3.2% LFD, Figure 14a), 
which was additionally confirmed by  immunohistochemistry (data not shown).  
We observed that in LFD mice, all F4/80+ cells were also MR+, compared to only 65% 
MR+ of F4/80+ in HF mice (wt: 62.5% ± 3.9%, P = 0.0019; spp1: 69.5% ± 3.9%, P = 
0.00047, Figure 14d) thereby suggesting the appearance of a F4/80+MR- cell population 
upon high-fat feeding. According to a recent publication, CD11c+ macrophages 
accumulate in the AT of diet-induced obese mice (116). In our experiments, the 
percentage of F4/80+CD11c+ macrophages in HFD (wt: 33.3% ± 0.9%; spp1: 31.7% ± 
3.7%) was three fold higher than that of LFD control mice (wt: 9.5% ± 2.3%, P = 
0.00023; spp1: 5.6% ± 2.2%, P = 0.0032, Figure 14e) confirming results obtained by 
Lumeng et al (116). Moreover, cells were gated for MR+ cells and analyzed for CD11c 
coexpression. We observed that in the MR+ population, CD11c was equally elevated as 
in the total F4/80+ cell population (HFD: wt: 33.3 ± 0.9%, spp1: 31% ± 3.8%; LFD: wt: 
13.5% ± 2%, P < 0.00001 ; spp1: 10.5% ± 1.5%, P = 0.013, Figure 14f). Finally, 
expression of CD51 and CD44 was significantly upregulated in HFD mice (CD51: wt: 
539.4 ± 25.4; spp1: 455.9 ± 64.7; CD44: wt: 2043.8 ± 155.4; spp1: 1877.4 ± 300.6) 
compared to LFD mice (CD51: wt: 140.7 ± 18.5, P < 0.0001; spp1: 147 ± 21.1, P = 
0.03; CD44: wt: 782.7 ± 155.4, P = 0.0044; spp1: 684.3 ± 34.9, P = 0.036; Figure 14i, 
j)  
However, none of the investigated surface markers was altered in spp1 knockout mice 
compared to wt mice, indicating that there are no alterations in ATM number, OPN 
receptor, and activation marker expression upon OPN deficiency.  
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Figure 14. Analysis of murine ATM 
populations. AT SVC (n=9) of C57BL/6J 
mice on normal or high-fat diet were 
stained for F4/80, MR, CD11c, CD51, and 
CD44, and expression of  surface markers 
analyzed by flow cytometry. Percentages of 
cells positive for F4/80 (a), MR (c), MR of 
F4/80+ (d), CD11c of F4/80+ (e), CD11c of 
MR+ (f) or mean fluorescence intensity 
(MFI) of F4/80+ (b), CD11c+ of F4/80+ (g), 
MR+ (h), CD51+ (i), and CD44+ (j) is 
shown. *P < 0.05, **P < 0.01, ***P < 
0.001 versus respective LF mouse. 
 
4.2 The effect of OPN on adipocytes 
 
Spp1 knockout mice display improved insulin sensitivity compared to wt mice. In order 
to evaluate a possible influence of OPN on adipocyte insulin responsiveness, we treated 
murine 3T3-L1 and human adipocytes with OPN for 48 h. As a control, cells were 
treated with TNFα which has repeatedly been shown to inhibit insulin-induced glucose 
uptake in adipocytes (116, 140). Insulin sensitivity was assessed by insulin-stimulated 
2-deoxyglucose uptake. We observed that OPN did not affect glucose uptake in 3T3-L1 
cells, and only a slight inhibition of insulin sensitivity was observed in human 
adipocytes (P = 0.056). TNFα effectively interfered with insulin-induced glucose 
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uptake in both model systems (Figure 15). 
Impaired adipocyte differentiation results in malfunctioning adipocytes with reduced 
lipid accumulation and insulin-induced glucose transport capabilities.  Previous studies 
have suggested that PPARγ expression, which is induced during adipocyte 
differentiation, suppresses OPN transcription in macrophages (141) and adipocytes 
(129), leading to decreased OPN expression during adipocyte differentiation. Thus, we 
investigated the effect of OPN on adipocyte differentiation. Human preadipocytes were 
differentiated with or without the addition of OPN to the medium. At differentiation end 
points, cells were examined morphologically and gene expression of adipocyte 
differentiation markers as well as adiponectin was measured via RT-qPCR. 
Morphological examination revealed no difference between OPN-treated and untreated 
adipocytes (Figure 16), yet there was a trend of a decrease in the expression of the 
adipocyte differentiation markers PPARγ (82% ± 11.9%, P = 0.14) and GLUT4 (82% ± 
14.4%, P = 0.23, Figure 17). Adiponectin is associated with increased adipocyte 
differentiation capacity and insulin sensitivity and its expression was shown to be 
decreased in obesity. Here we observed that adiponectin expression is decreased in 
adipocytes chronically treated with OPN (75% ± 6.3%, P = 0.0034, Figure 17).  
To conclude, these results indicate that OPN has no profound effect on insulin 
sensitivity, but a moderate effect on adipocyte differentiation capacity and adipoQ 
expression. 
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Figure 15. Insulin-induced glucose uptake in 3T3-L1 
(a,b) and human adipocytes (c). Differentiated 
adipocytes were treated with 500 ng/ml OPN or 25 
ng/ml TNF for 48 hours prior to the experiment. 2-DG 
uptake was assessed after 30 (a,b) or 15 (c) minutes 
without (grey bars, (a)) or with (black bars, (a)) insulin 
(1 µM) stimulation. Data are expressed as mean ± SE 
of duplicate (c) or triplicate (a,b) experiments ((a,b) 
n=3; (c) n=6). **P < 0.01 compared to untreated. 
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Figure 16. Morphology of human preadipocytes differentiating with or without 500 ng/ml OPN. 
(magnification: x100 (top), x 1,000 (bottom).  
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Figure 17. Adipocyte marker expression in OPN-treated human adipocytes. Human preadipocytes were 
differentiated with (red bars) or without (black bars) the addition of 500 ng/ml OPN to the culture 
medium. At d10 of differentiation, cells were harvested and gene expression of GLUT4, PPARγ and 
adipoQ quantitatively assessed by RT-qPCR (n=4). Data are presented as relative gene expression 
normalized to 18S rRNA gene expression and are expressed as mean ± SE. **P < 0.01, compared to 
control. 
 
4.3 Coculture of spp1 and wt macrophages with 3T3-L1 adipocytes 
 
Our results indicate that OPN is an activator of ATMs but does not affect adipocyte 
function. In a previous publication, macrophages have been shown to interfere with 
adipocyte insulin sensitivity in coculture experiments (113). We hypothesized that spp1 
knockout macrophages may have lost this ability if OPN is crucial for macrophage 
activation in AT inflammation. In order to address this question, we employed indirect 
coculture experiments with AT SVC derived from obese wt C57BL/6J or spp1 
knockout mice.  
 Adherent SVC (105 cells/insert) were cultured in the upper chamber of a 
permeable cell culture insert with 3T3-L1 adipocytes in the lower chamber. The 
permeable membrane in this culture system permits secreted factors to pass between the 
two cell types but does not permit direct cell – cell contact. As shown in Figure 18, 
coculture with both wt and spp1 SVC led to an increase in basal glucose uptake, which 
decreased the fold change in insulin-stimulated glucose uptake. There was no difference 
between wt and spp1 macrophage-mediated inhibition of insulin response indicating 
that macrophage-inherent OPN is not essential for interference with adipocyte function.  
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Since OPN is an activator of ATMs, we sought to examine whether treatment of 
macrophage – adipocyte cocultures with OPN had any effect on adipocyte insulin 
resoponsiveness compared to nontreated cocultures. Therefore, SVC from wt mice fed a 
normal diet (ND) were isolated and cocultured with adipocytes as described above, and 
treated with OPN or left untreated as a negative control. Similar to the HFD-SVC, ND-
SVC led to an increased basal glucose uptake of 3T3-L1 adipocytes, thereby resulting in 
a decreased fold stimulation index of insulin-induced glucose uptake. However, there 
was no difference between OPN-treated and untreated coculture systems.  
 
 
 
 
Figure 18. Insulin-stimulated 2-deoxyglucose uptake in 3T3-L1 adipocytes cocultured with murine SVC.  (a) 
Murine SVC obtained from HFD wt and  spp1 mice (n=4) and (b) murine SVC obtained from lean wt mice 
were cultured in the upper cell culture insert with differentiated 3T3-L1 adipocytes in the lower chamber for 
two days. 2-DG uptake was assessed with and without insulin stimulation. Experiments were performed in 
duplicate (a) or triplicate (b) and data are expressed as means ± SE. 
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5 Discussion 
 
Several lines of evidence have clearly demonstrated that obesity is accompanied by a 
state of chronic, low-grade inflammation that contributes to insulin resistance and type 2 
diabetes (10). It has also been shown that obesity leads to macrophage accumulation in 
AT and it is likely that macrophages are the main contributors to the inflammatory 
responses observed in obesity (34, 60). OPN is a chemokine-like, extracellular matrix-
associated protein involved in monocyte motility and inflammatory immune responses 
(130). According to two recent studies (129, 131), OPN expression is increased in the 
AT of obese mice and OPN deficiency leads to improved insulin sensitivity as well as 
decreased AT inflammation (129). It was the aim of this thesis to investigate the 
influence of OPN on ATMs and adipocytes in order to elucidate the mechanisms by 
which OPN contributes to insulin resistance.  
A crucial role of OPN in the attraction and activation of murine ATMs has already been 
proposed (129). Therefore we focused our experiments on human model systems. We 
report here that OPN is a potent activator of human macrophages.  
  Human ATMs were previously characterized by CD14 and MR coexpression, 
whereas CD14+MR- cells found in obese AT were thought to be contaminating blood 
monocytes (118). Consistent with this notion, we show here that on the mRNA level, 
CD14+MR+ ATMs express larger quantities of OPN and other cytokines when 
compared to CD14+MR- monocytes. Hence, in this study CD14+MR+ cells were 
regarded as ATMs. Isolation of sufficient amounts of human ATMs is crucial for 
investigating their nature and function. We applied here two different methods of ATM 
purification, magnetic cell sorting (MACS) and flow cytometry, and compared their 
responsiveness to OPN and other cell stimulators in terms of cytokine secretion. 
Magnetic cell sorting is a fast and easy procedure for the enrichment of cell populations 
via specific surface molecules.  However, if analyses of ATM function are required, 
only anti-CD14 magnetic beads can be used since ATMs magnetically isolated via MR 
have been shown not to be functionally intact (own unpublished observations). 
Therefore, conclusions from experiments with MACS-separated ATMs are limited, 
because ATMs isolated that way contain considerable numbers (∼ 20%) of MR- 
contaminating blood monocytes.  
 MACS-sorted CD14+ cells basally secreted IL-10, Mcp-1 and TNFα, and were 
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stimulated by IFNγ to further increase Mcp-1 and TNFα, whereas OPN had little effect. 
Remarkably, the CD14-depleted fraction also produced considerable amounts of Mcp-1 
with a tendency to be stimulated further. This phenomenon may point towards an 
important role of CD14- cells of the AT (preadipocytes, endothelial cells) in the 
attraction of macrophages. 
Flow cytometry yields a much higher purity of ATMs, since sorting via both CD14 and 
MR is possible, but there were remarkable differences in cytokine production compared 
to MACS-sorted cells. First, CD14+MR+ cells secreted hardly any IL-10 and TNFα on 
the basal level. Moreover, they had only very little potential to be activated further: IL-
10 was the only cytokine that could be induced by OPN or LPS, and IFNγ had, in 
contrast to MACS-sorted cells, no effect at all.  
 Also, the CD14+MR- sorted fraction secreted hardly any IL-10 or TNFα and basal 
Mcp-1 secretion was lower in MR- than in MR+ cells, correlating with the gene 
expression results. However, the MR- population had a higher capability of being 
stimulated than the MR+ population. If MR+ cells are referred to as „real“ ATMs and 
MR- cells are considered as contaminating blood monocytes, this may appear 
reasonable, since CD14+MR+ cells are probably preactivated by inflammatory processes 
in the AT and therefore show limited capacity of being activated further compared to 
CD14+MR- cells that were not preactivated.  
Nevertheless, this also suggests that cytokine production of stimulated MACS-sorted 
CD14+ cells may be, at least in part, attributed to MR- non-ATMs. Because of the 
discrepancies observed in cytokine production of the two differently sorted ATMs, a 
major resulting question is, which purification method is to be preferred. Whereas 
MACS-sorted CD14+ cells contain approximately 20% MR- contaminating cells, 
FACS-sorted ATMs are of high purity but have obviously lost their capacity of being 
stimulated. However, it can be assumed that either method, especially in combination 
with subsequent cultivation, leads to alterations in cell function that does not necessarily 
reflect the in vivo situation.  
 
Since it is difficult to obtain high amounts of ATMs by the mentioned methods, we used 
human model macrophages in our further experiments. We showed that OPN leads in a 
concentration-dependent manner to the production of the inflammatory mediators 
TNFα and Mcp-1, and the anti-inflammatory cytokine IL-10. The exact cytokine 
secretion pattern is dependent on the type of model macrophage activation: Whereas 
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M2 macrophages do not produce anti-inflammatory IL-10 upon OPN-stimulation and 
do not show any OPN-LPS synergism, M1 macrophages do so. Although M2 
macrophages resemble ATMs phenotypically more than M1 macrophages, ATMs 
cannot definitely be assigned to the one or the other type, since M1 and M2 are only 
two extremes of a continuum of functional stages of macrophages (103). At any rate, 
the results demonstrate clearly that OPN leads to the production of inflammatory 
mediators in model macrophages as well as ATMs. Exceptionally high is the production 
of Mcp-1 in response to OPN which suggests that a main role of OPN in AT 
inflammation could be the attraction of immune cells via induction of chemokines. The 
production of the anti-inflammatory cytokine IL-10, which has been shown to have 
beneficial effects on insulin sensitivity (116), indicates that the response to OPN is not 
exclusively inflammatory, though.  
 
On the signaling level, we found that OPN signals independently from IRAK-1 
degradation, which is a central event in LPS-mediated TLR4 signaling. This finding is 
important since  previously doubts have been raised that results on OPN-induced 
immune cell activation may be due to LPS contamination of OPN preparations (128). 
Moreover, OPN induces  activation of MAP Kinase pathways and, to a minor extent, 
activation of the NfκB pathway, whereas analyses of time courses showed that OPN 
signals somewhat delayed compared to the classical cell stimulator LPS.  
 
Since according to our data, OPN deficiency reduces AT inflammation without 
affecting macrophage cell number, we aimed to investigate an influence of OPN on 
ATM phenotype as detected by CD11c, MR, and OPN receptor expression. However, 
investigated surface markers were not altered in ATMs of spp1 knockout compared to 
wt mice. We detected considerable upregulations of CD11c, an AT inflammation 
marker, and the putative OPN receptors CD51 and CD44 in high-fat diet fed mice. In 
further experiments, it would be interesting to investigate which of these ATM 
populations is the OPN-expressing one. We moreover found that the percentage of MR+ 
of F4/80+ decreases after HF feeding, indicating the emergence of a novel F4/80+MR- 
cell population also independent of OPN. We cannot interpret the importance of this 
population at the moment, but further experiments will reveal potential differences in 
gene expression or cytokine production between these two cell types. Macrophage 
downregulation of MR is a characteristic of a shift from the alternative, anti-
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inflammatory M2 to the classical, inflammatory M1 type macrophage. Therefore, a 
downregulation of MR, associated with an increased abundance of detrimental M1 type 
macrophages in the AT upon high-fat diet seems plausible. In addition, the finding of 
MR- ATMs in mice is particularly interesting since we have used MR as a marker for 
the isolation of human ATMs. The obvious existence of a MR- ATM population in mice 
evokes the question whether there may also be human MR- ATMs that have not been 
determined yet. Although this consideration seems interesting, it is rather unprobable 
since we were never able to detect any MR- macrophage by immunohistochemistry of 
human AT sections (118).   
 
In human preadipocyte cultures, we found that OPN-treatment during differentiation led 
to a decreased adiponectin gene expression in differentiated adipocytes. Since decreased 
adiponectin expression has been implicated in the pathogenesis of obesity and type 2 
diabetes in humans (142), this may indicate that OPN promotes an insulin resistant state 
by downregulating adiponectin. As however adiponectin expression was not linked to 
OPN deficiency in mouse experiments (own unpublished observations) and OPN had 
no other significant effects on insulin resistance and differentiation capacity of 
adipocytes, we conclude that OPN does not directly influence adipocyte function.  
 
Since we have shown here that OPN is an activator of macrophages and, according to a 
recent study, OPN is directly mediating ATM accumulation, it may be hypothesized 
that OPN is affecting insulin resistance via activation and attraction of macrophages. 
Therefore we investigated if OPN has an effect on adipocyte insulin sensitivity in 
macrophage - adipocyte coculture systems. Interestingly, OPN-deficient murine ATMs 
interfere with adipocyte insulin responsiveness as do wt ATMs. This primarily suggests 
that macrophages do not need OPN to become activated. Another explanation may be 
that the OPN concentration in the culture medium is sufficient to activate both wild type 
and OPN-deficient ATMs as a component of an activating cytokine cocktail. Although 
the main OPN-expressing cell type in human and murine AT is the macrophage, we 
cannot exclude the possibility that secretion of small amounts of OPN into the medium 
by 3T3-L1 adipocytes used in our coculture is activating macrophages sufficiently to 
induce insulin resistance in the adipocyte.  
Moreover, the inhibitory effect of macrophages on adipocyte insulin sensitivity was not 
enhanced by OPN treatment of the coculture. The phenomenon that OPN  is an activator 
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of macrophages but does not induce sufficient activation of the macrophage in order to 
suppress insulin sensitivity appears surprising. This may partially be explained by the 
fact that macrophages isolated from the AT, an environment containing multiple 
cytokines and also OPN, are preactivated and can no longer be stimulated further.  
 Most probably, however, these results suggest that OPN treatment or deficiency 
does not have any effect on adipocyte insulin sensitivity in this experimental setup. 
Although OPN is capable to induce inflammatory reactions in murine and human 
macrophages, these alterations are, at least in-vitro, not directly linked to adipocyte 
insulin resistance.   
In conclusion, improved insulin sensitivity as observed in spp1 knockout mice is 
probably not caused by direct action of OPN on adipocytes or activation of ATMs by 
OPN. In a recent publication (129) it was shown that OPN deficiency impairs ATM 
accumulation and macrophage migration capacity. As a consequence, it may be 
considered possible that OPN is acting primarily via macrophage attraction rather than 
macrophage activation during obesity, but preliminary animal studies of our lab have 
shown no effect of OPN deficiency on ATM infiltration. Most probably, the mechanism 
linking OPN to insulin resistance are more complex and may involve additional 
molecules, cell types or organs. Therefore, other functions of OPN during obesity will 
have to be further investigated.  
 
6 Conclusion 
 
This thesis identifies OPN as an activator of human macrophages which are strongly 
supposed to play a role in the development of insulin resistance. OPN leads to increased 
cytokine production and activation of inflammatory signaling pathways in human model 
macrophages whereas human ATMs appear to be prestimulated and can only partially 
be activated further. By contrast, OPN had no profound effect on human or murine 
adipocytes. Our results indicate that OPN may exert part of its role in obesity-associated 
adipose tissue inflammation and insulin resistance via induction of the attraction of 
macrophages into the AT and subsequent inflammatory cytokine production. Since 
OPN had no effect on insulin sensitivity in macrophage – adipocyte cocultures, the 
mechanisms that ultimately lead to insulin resistance are presumably more complex and 
may involve other tissues and organs.   
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I am now to realize that I have come to the end of my thesis. I would like to finish it 
with a citation that I recalled everytime I lost faith in myself:  
 
„If you think you can do a thing or if you think you can't do a thing, either way you're 
right.“ 
Henry Ford, US automobile industrialist (1863 - 1947) 
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9 Used Abbreviations 
 
ADD  adipocyte determination and differentiation factor 
AP  activator protein 
APS  ammonium persulfate 
AT  adipose tissue 
ATM   adipose tissue macrophage 
BAT  brown adipose tissue 
BCA  bicinchoninic acid 
BMI  body mass index 
BSA  bovine serum albumine 
CAP  Cbl-associated protein 
CD  cluster of differentiation 
cDNA  complementary deoxyribonucleic acid 
CCL  chemokine ligand 
CNS  central nervous system 
CRP  C-reactive protein 
DG  Deoxyglucose 
DMEM Dulbecco’s modified Eagle’s medium 
dNTP  deoxyribonucleotide triphosphate 
DTT  dithiotreitole 
ER  endoplasmic reticulum 
ERK  extracellular signal-regulated kinase 
FACS  fluorescence activated cell sorting 
FAK  focal adhesion kinase 
FBS  fetal bovine serum 
FCS  fetal calf serum 
GLUT  glucose transporter 
Grb2  growth factor receptor-bound protein 2 
HBSS  Hank’s buffered salt solution 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFD  high-fat diet 
HRP  horseradish peroxidase 
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IBMX  isobutylmethylxanthine 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
IκB  inhibitor of NF-κB 
IKK  IκB kinase 
IRAK  interleukin-1 receptor associated kinase 
IRS  insulin-receptor substrate 
JNK  c-Jun N-terminal kinase 
KRPH  Krebs Ringer phosphate HEPES buffer 
LFD  low-fat diet 
LIPE  hormone-sensitive lipase 
LPS  lipopolysaccharide 
M1  classically activated macrophage 
M2  alternatively activated macrophage 
MACS  magnetic-activated cell separation 
MAP  mitogen-activated protein 
Mcp  monocyte chemoattractant protein 
MEKK mitogen ERK kinase kinase 
MFI  mean fluorescence intensity 
MR  mannose receptor 
NEFA  nonesterified fatty acid 
NF-κB  nuclear factor-κB 
O/N  overnight 
OPN   osteopontin 
PAGE  polyacrylamid gel electrophoresis 
PAI  plasminogen activator inhibitor 
PBMC  peripheral blood mononuclear cell 
PBS  Dulbecco’s phosphate buffered saline 
PCR  polymerase chain reaction 
PH  pleckstrin homology 
PI(3)K  phosphatidylinositol-3-kinase 
PKB  protein kinase B 
PPAR  peroxisome proliferator-activated receptor 
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PTPase protein tyrosine phosphatase 
RNA  ribonucleic acid 
ROS  reactive oxygen species 
RT  room temperature 
RT-qPCR quantitative real-time PCR 
SDS  sodium dodecyl sulfate 
SE  standard error 
SH2  Src homology 2 
Shc  Src homologous and collagen protein 
SLC2A4 solute carrier family 2 member 4 
SPP  secreted phosphoprotein 
SREBP sterol regulatory element binding protein 
SVC  stromal vascular cell 
TEMED N,N,N',N'-Tetramethylethylenediamine 
TLR  toll-like receptor 
TNF  tumor necrosis factor 
WAT  white adipose tissue 
wt  wild-type 
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